Company:  TROVAGENE, INC. (TROV)
Form Type:  8-K
Filing Date:  4/16/2018 
CIK:  0001213037 
Address:  11055 FLINTKOTE AVENUE 
City, State, Zip:  SAN DIEGO, California 92121 
Telephone:  858-952-7570 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$4.04  
Change: 
-0.22 (-5.16%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$16.25M
Trade TROV now with 

© 2019  
Description of Business
We are a clinical-stage, oncology therapeutics company, taking a precision medicine approach to develop targeted therapies for the treatment of patients with leukemias, lymphomas and solid tumor cancers. By integrating biomarkers into our clinical development programs, we will be able to identify patients who are most likely to respond to treatment across a number of cancer types and associated indications where there is a significant medical need to provide new therapeutic options. Our drug candidate, onvansertib (formerly known as PCM-075), is a first-in-class, 3rd generation, oral and highly-selective Polo-like Kinase 1 ("PLK1") adenosine triphosphate ("ATP") competitive inhibitor. PLK1 is essential for precisely regulating the cell division and maintaining genome stability in mitosis (cell division), spindle assembly, and DNA damage response.
Register and access this filing in:     
  FORM 8-K
    SECTION 8 OTHER EVENTS
      Item 8.01 Other Events.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits
    SIGNATURE
  EXHIBIT 99.1